Merck Moves Forward With Odanacatib Filing; FDA Accepts MK-3475 Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
At a May 6 investor day, Merck’s R&D head Roger Perlmutter revealed the safety issues that have been delaying the company’s late-stage osteoporosis drug and tried to renew confidence in the treatment.